启明星 | 明慧医药Pre-IPO轮融资1.31亿美元，启明创投联合领投 | Bilingual

Swipe Left for the English Version

日前，专注于肿瘤及自身免疫性疾病领域的临床后期生物制药公司明慧医药宣布，已完成1.31亿美元的Pre-IPO轮融资。本轮融资由启明创投联合领投。

融资资金将用于推进明慧医药临床项目的发展，重点包括PD-1/VEGF双特异性抗体及其与抗体偶联药物（ADC）联用的治疗策略。同时支持明慧医药外用JAK抑制剂在中国的商业化上市。

明慧医药首席执行官曹国庆博士表示："此次融资是公司发展历程中的重要里程碑。我们将继续推进具有全球竞争力的创新管线建设，迈入新的发展阶段。 感谢所有投资人对我们的认可与支持，我们将坚定不移地致力于为全球患者提供能改善治疗效果的创新药物。"

启明创投合伙人、医疗创新行业共同负责人陈侃博士表示："明慧医药围绕未被满足的临床需求，建立了极具实力的创新药物管线。我们很高兴能够助力公司加速发展，将变革性疗法惠及全球患者。"

本轮融资由新晋投资方OrbiMed和启明创投联合领投，泰福资本继续投资，博远资本、时真资本、五源资本及君熠投资等7家新投资方参与投资。

Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing Co-Led by Qiming Venture Partners

Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, announced the closing of a USD 131 million Pre-IPO financing co-led by Qiming Venture Partners. Representatives from Qiming Venture Partners will join the company's Board of Directors.

Proceeds will be used to advance the company's clinical programs, with a particular focus on its PD-1/VEGF bispecific antibody and combination strategies with antibody-drug conjugates (ADCs). The funds will also support the planned commercial launch of its topical JAK inhibitor in China.

"This financing marks an important milestone as we continue to advance a globally competitive pipeline and enter our next stage of growth," said Dr. Guoqing Cao, Chief Executive Officer of Minghui. "We're grateful for the confidence and support of our investors and remain committed to delivering innovative medicines that improve outcomes for patients worldwide."

"Minghui has built a compelling portfolio of novel drug candidates targeting critical unmet medical needs," said Dr. Kan Chen, Partner and Co-lead of Healthcare at Qiming Venture Partners. "We are pleased to support its continued growth and help bring transformative therapies to patients around the world."

This round is co-led by new investors OrbiMed and Qiming Venture Partners. Further support came from existing investor TF Capital, and seven new investors, including BioTrack Capital, New Day Fund, 5Y Capital, and Wider Link Enterprise Investment limited.

往 期 回 顾

启明观点 | 启明创投陈侃：中国创新药出海达到历史新高，创新药投资向何处去？ 启明星 | 5家启明创投投资企业入选BEYOND Awards医疗科技超越榜单及大健康领航榜单 启明荣誉 | 启明创投及投资人入选36氪2025年度中国股权投资行业投资机构系列名册

启明创投成立于2006年。目前，启明创投旗下管理11只美元基金，7只人民币基金，已募管理资产总额达到95亿美元。自成立至今，专注于投资科技(Technology)、医疗创新(Healthcare)等行业早期和成长期的优秀企业。

截至目前，启明创投已投资超过580家高速成长的创新企业，其中有超过210家分别在美国纽交所、纳斯达克，香港交易所，上交所及深交所等交易所上市，或通过并购等方式退出，有80多家企业成为行业公认的独角兽或超级独角兽企业。

启明创投投资企业中，很多已经成长为各自领域中最具影响力的公司，包括小米集团（01810.HK）、美团（03690.HK）、哔哩哔哩（NASDAQ:BILI, 09626.HK）、知乎（NYSE:ZH, 02390.HK）、石头科技（688169.SH）、优必选（09880.HK）、文远知行（NASDAQ:WRD）、影石创新（688775.SH）、甘李药业（603087.SH）、泰格医药（300347.SZ, 03347.HK）、再鼎医药（NASDAQ:ZLAB, 09688.HK）、康希诺生物（688185.SH, 06185.HK）、Schrödinger（NASDAQ:SDGR）、惠泰医疗（688617.SH）、三友医疗（688085.SH）、艾德生物（300685.SZ）、贝瑞基因（000710.SZ）、神州细胞（688520.SH）、圆心科技、英矽智能、宜联生物、礼新医药、智谱AI、阶跃星辰、壁仞科技等。